Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)

被引：0

作者：

Chen, T. W-W. ^{[1
]}

Hsu, C-L. ^{[2
]}

Lee, J-C. ^{[3
]}

Yen, C-C. ^{[4
]}

Hong, R-L. ^{[5
]}

Chen, S-C. ^{[6
]}

Yu, C-W. ^{[7
]}

Chen, M-L. ^{[5
]}

Hsu, M-C. ^{[5
]}

Kung, T-F. ^{[6
]}

Cheng, A-L. ^{[5
]}

机构：

[1] Natl Taiwan Univ Hosp, Coll Med, Oncol Dept, Taipei, Taiwan

[2] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan

[3] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan

[4] Taipei Vet Gen Hosp, Dept Med Oncol, Taipei, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[6] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan

[7] Natl Taiwan Univ Hosp, Dept Med Imaging, Taipei, Taiwan

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.1595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1492MO

引用

页码：S1229 / S1229

页数：1

共 3 条